Clinical Trials Sponsored by Intersect ENT

Total 3763 results

Intersect ENT

Completed

A Clinical Evaluation of PROPEL® Contour Sinus Implant (EXPAND)

Chronic Rhinosinusitis (Diagnosis)

United States
Intersect ENT

Completed

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

Chronic Rhinosinusitis (Diagnosis)

United States
Intersect ENT

Completed

Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis

Chronic Sinusitis

United States
Intersect ENT

Completed

A Clinical Evaluation of the Sinexus Intranasal Splint Following Functional Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis (CONSENSUS II)

Chronic Sinusitis

United States
Intersect ENT

Completed

Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia (EXCEED)

Chronic Sinusitis

United States
Intersect ENT

Completed

Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)

Chronic Sinusitis | Nasal Polyposis

United States
Intersect ENT

Completed

In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia (FRONTIER)

Chronic Sinusitis

United States
Intersect ENT

Completed

S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps (RESOLVE_II)

Chronic Sinusitis | Nasal Polyposis

United States
Intersect ENT

Completed

Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps (RESOLVE)

Chronic Sinusitis | Nasal Polyps

United States
Intersect ENT

Completed

Safety and Performance of the Steroid-Releasing S8 Sinus Implant (S8PK)

Chronic Sinusitis

United States
Intersect ENT

Completed

A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis (ADVANCE II)

Chronic Sinusitis

United States
ENT and Allergy Associates, LLP
Intersect ENT

Completed

The PIO (Propel In Office) III Study of In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery

Chronic Sinusitis

United States
Intersect ENT
Advance Research Associates

Completed

Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus (PROGRESS)

Chronic Sinusitis

United States
Collin County Ear Nose & Throat
Intersect ENT

Completed

The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant

Chronic Sinusitis, Ethmoidal

United States
Intercept Pharmaceuticals

Terminated

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, Spain, Canada, United Kingdom, France, Germany, Austria, Netherlands
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Intercept Pharmaceuticals

Completed

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) (AESOP)

Primary Sclerosing Cholangitis (PSC)

United States, Italy
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Intercept Pharmaceuticals

Completed

Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment

United States
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Intercept Pharmaceuticals

Completed

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Spain, France, Australia, New Zealand, Puerto Rico, Germany, Canada, United Kingdom, Hungary, Poland, Ukraine
Intercept Pharmaceuticals

Terminated

Obeticholic Acid in Pediatric Subjects With Biliary Atresia (CARE)

Biliary Atresia

Israel, United Kingdom, Poland, Belgium, France, Germany, Italy, Netherlands, Spain
Intercept Pharmaceuticals

Completed

Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

Healthy

United States
Intercept Pharmaceuticals

Not yet recruiting

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Biliary Atresia
Intercept Pharmaceuticals

Recruiting

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study (FRESH)

Alcohol Associated Hepatitis

United States, France, United Kingdom
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Primary Biliary Cholangitis

United States
Intercept Pharmaceuticals

Terminated

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Non Alcoholic Steatohepatitis (NASH)

United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
Intercept Pharmaceuticals

Completed

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
Intercept Pharmaceuticals

Completed

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) (CONTROL)

Nonalcoholic Steatohepatitis

United States
Intercept Pharmaceuticals

Completed

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

Healthy

United States
Intercept Pharmaceuticals

Completed

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

Fatty Liver | Diabetes Mellitus, Type II

United States
Intelect Medical, Inc.

Withdrawn

Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease (SAGE)

Parkinson's Disease

United States
Intersci Research Association, Austria

Unknown

Urinary Steroid Metabolites in Autism

Autism Spectrum Disorder | Autism

Austria
Children's Fractures Interest Group, Denmark

Recruiting

Non-operative Treatment of Pediatric Lateral Humeral Condyle Fractures (NOTICE)

Fracture Humerus | Physeal Fracture

Denmark
Children's Fractures Interest Group, Denmark

Recruiting

Use of the Bioabsorbable Activa IM-Nail™ in Pediatric Diaphyseal Forearm Fractures

Child, Only | Implant Complication | Forearm Fracture | Fracture Healing | Fracture Fixation, Intramedullary

Denmark
Association Accompagnement pour un Internet en...
UCB France S.A.

Completed

CARNet : Self-Monitoring and Co-driving in Rheumatology With Internet : Rheumatoid Arthritis Cohort (Usual Care Study) (CARNet)

Rheumatoid Arthritis

France
Universitaire Ziekenhuizen KU Leuven
Intercept Pharmaceuticals

Recruiting

The Effect of Obeticholic Acid in Healthy Volunteers (OCARINA)

Healthy

Belgium
Stanford University
End Allergies Together (EAT)

Completed

Effect of Different Skin Creams on TEWL

Dermatitis, Atopic

United States
National University, Singapore
INTELLECT COMPANY PTE. LTD.

Completed

Effectiveness of a Self-guided Mobile Phone Application in Improving the Way we See Ourselves and Our Bodies

Body Image

Singapore
National University of Singapore
Intellect Pte. Ltd.

Completed

Effectiveness of a Self-guided Mobile Application in Improving Wellbeing and Stress Coping

Stress

Singapore
Hacettepe University
Interact Medical Technologies Inc.

Not yet recruiting

Upper Extremity Robot-Assisted Therapy in Stroke Patients

Stroke | Upper Extremity

Turkey
National University of Singapore
Intellect Pte. Ltd.

Active, not recruiting

Effectiveness of a Self-guided Mobile Application in Improving Obsessive Compulsive Disorder Symptoms

Obsessive-Compulsive Disorder

Singapore
West Side ENT

Terminated

Minimally Invasive Tongue Suture For Obstructive Sleep Apnea

Obstructive Sleep Apnea | Upper Airway Resistance Syndrome

United States
West Side ENT

Withdrawn

Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome

Obstructive Sleep Apnea | Gastroesophageal Reflux | Upper Airway Resistance Syndrome
SAMEY
Axonal-Biostatem

Unknown

A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis Treated With Obeticholic Acid in Real Life (OCARELIFE)

Primary Biliary Cholangitis

France
BrightView LLC
DynamiCare Health; Interact for Health

Unknown

A Digital Smoking Cessation Intervention for Adults With Substance Use Disorder

Tobacco Use Disorder | Substance Use Disorders

United States
VTan
The Intellect Company

Completed

Self-help App and Wellbeing

Anxiety and Worry

Singapore
University of Milano Bicocca
Intercept Pharmaceuticals; Laboratoires Mayoly Spindler

Recruiting

National Database on Primary Biliary Cholangitis (PBC322)

Primary Biliary Cholangitis

Italy

Clinical Trials Sponsored by Intersect ENT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations